Document Detail


Successful chemotherapeutic treatment of diencephalic syndrome with continued tumor presence.
MedLine Citation:
PMID:  10897816     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 7-month-old infant with typical features of diencephalic syndrome (DES) associated with a hypothalamic mass, most probably a glioma, was treated with chemotherapy. The tumor showed clear shrinkage, but after more than 2 years regrowth was noted. During the treatment period the child regained normal growth and became free of symptoms. As radiation therapy, especially at a young age, has significant adverse effects and a neurosurgical approach to the diencephalic region also has the potential to cause significant sequelae, a chemotherapeutic option, when it exists, is preferred. Thus, in an infant in whom a glioma is suspected to be the cause of the DES, based on the clinical picture and the neuroimaging appearance, chemotherapy should be considered the primary therapeutic modality. Even if its effect is temporary, its use is well justified. The most appropriate treatment protocol still needs to be determined.
Authors:
A Shuper; I Bloch; L Kornreich; G Horev; S Michowitz; R Zaizov; I Cohen
Related Documents :
9180056 - Ethical decision-making in newborn infants.
17448746 - Three recurrent episodes of malrotation in an infant.
7850446 - The use of long-acting oxytetracycline for the treatment of ovine footrot.
6658456 - Memory retrieval: a time-locked process in infancy.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  13     ISSN:  0888-0018     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:    1996 Sep-Oct
Date Detail:
Created Date:  2000-08-25     Completed Date:  2000-08-25     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  443-9     Citation Subset:  IM    
Affiliation:
National Center for Pediatric Hematology/Oncology, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abducens Nerve Diseases / etiology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brain Neoplasms / complications*,  drug therapy
Carboplatin / administration & dosage
Dactinomycin / administration & dosage
Diencephalon / pathology*
Failure to Thrive / etiology*
Glioma / complications*,  drug therapy
Growth Disorders / etiology*
Humans
Hyperkinesis / etiology*
Infant
Magnetic Resonance Imaging
Male
Neoplasm Recurrence, Local
Nerve Compression Syndromes / etiology
Nystagmus, Pathologic / etiology*
Remission Induction
Strabismus / etiology
Vincristine / administration & dosage
Weight Gain
Chemical
Reg. No./Substance:
41575-94-4/Carboplatin; 50-76-0/Dactinomycin; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance the...
Next Document:  Human herpesvirus-6 (HHV-6)-associated hemophagocytic syndrome.